// STATE LEGISLATION TRACKER

Washington HB 1197: Making 2023-2025 fiscal biennium second supplemental operating appropriations.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: In committee

State: Washington
Bill: HB 1197
Session: 2025-2026
Filed: 2025-01-08
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Washington HB1197 is a supplemental operating budget bill for the 2023-2025 fiscal biennium. Based on the title, subjects, and status, it does not appear to directly affect compounded peptides, off-label prescribing, telehealth, NP or naturopath scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No clear change to peptide access or prescribing rules
No apparent change to telehealth prescribing authority
No apparent change to NP or naturopath scope
No apparent compounding or pharmacy rule change
This looks like a general state budget bill

What to Watch For

Note Budget bills can fund health agencies, but no peptide-specific issue is visible from the provided bill info.

Note Watch for amendments or budget provisos that mention pharmacies, DOH, prescribing, or controlled substances.

Note The bill is still retained in its current status, so its practical effect is not final.

Where the Bill Stands

The bill was reintroduced and retained in its current status after being referred to the House Appropriations Committee.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws